Literature DB >> 25027516

Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it?

G Barosi1, M-J Zhang2, R Peter Gale3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25027516     DOI： 10.1038/leu.2014.220

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Unique features of primary myelofibrosis in Chinese.

Authors:  Zefeng Xu; Robert Peter Gale; Yue Zhang; Tiejun Qin; Huishu Chen; Peihong Zhang; Tianjiao Zhang; Liu Liu; Shiqiang Qu; Zhijian Xiao
Journal:  Blood       Date:  2012-01-18       Impact factor: 22.113

2.  Long-term outcome of treatment with ruxolitinib in myelofibrosis.

Authors:  Ayalew Tefferi; Mark R Litzow; Animesh Pardanani
Journal:  N Engl J Med       Date:  2011-10-13       Impact factor: 91.245

3.  Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.

Authors:  Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael W N Deininger; Carole B Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth O Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; William Sun; Victor Sandor; Hagop M Kantarjian
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

4.  Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis.

Authors:  Francisco Cervantes; Alessandro M Vannucchi; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Andres Sirulnik; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard S Levy; Francesco Passamonti; Tiziano Barbui; Giovanni Barosi; Claire N Harrison; Laurent Knoops; Heinz Gisslinger
Journal:  Blood       Date:  2013-10-30       Impact factor: 22.113

5.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

6.  Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.

Authors:  Srdan Verstovsek; Hagop M Kantarjian; Zeev Estrov; Jorge E Cortes; Deborah A Thomas; Tapan Kadia; Sherry Pierce; Elias Jabbour; Gautham Borthakur; Elisa Rumi; Ester Pungolino; Enrica Morra; Domenica Caramazza; Mario Cazzola; Francesco Passamonti
Journal:  Blood       Date:  2012-06-20       Impact factor: 22.113

7.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

8.  The prevention and treatment of missing data in clinical trials.

Authors:  Roderick J Little; Ralph D'Agostino; Michael L Cohen; Kay Dickersin; Scott S Emerson; John T Farrar; Constantine Frangakis; Joseph W Hogan; Geert Molenberghs; Susan A Murphy; James D Neaton; Andrea Rotnitzky; Daniel Scharfstein; Weichung J Shih; Jay P Siegel; Hal Stern
Journal:  N Engl J Med       Date:  2012-10-04       Impact factor: 91.245

9.  A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

Authors:  Francesco Passamonti; Francisco Cervantes; Alessandro Maria Vannucchi; Enrica Morra; Elisa Rumi; Arturo Pereira; Paola Guglielmelli; Ester Pungolino; Marianna Caramella; Margherita Maffioli; Cristiana Pascutto; Mario Lazzarino; Mario Cazzola; Ayalew Tefferi
Journal:  Blood       Date:  2009-12-14       Impact factor: 22.113

10.  Hypothesis: how do JAK2-inhibitors work in myelofibrosis.

Authors:  Ruben Mesa; Robert Peter Gale
Journal:  Leuk Res       Date:  2009-05-17       Impact factor: 3.156
View more
  11 in total

Review 1.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

Review 2.  New Concepts of Treatment for Patients with Myelofibrosis.

Authors:  Prithviraj Bose; Mansour Alfayez; Srdan Verstovsek
Journal:  Curr Treat Options Oncol       Date:  2019-01-24

3.  Ruxolitinib and survival improvement in patients with myelofibrosis.

Authors:  F Passamonti; A M Vannucchi; F Cervantes; C Harrison; E Morra; H Kantarjian; S Verstovsek
Journal:  Leukemia       Date:  2014-09-24       Impact factor: 11.528

4.  Phase 1/2 trial of glasdegib in patients with primary or secondary myelofibrosis previously treated with ruxolitinib.

Authors:  Aaron T Gerds; Tetsuzo Tauchi; Ellen Ritchie; Michael Deininger; Catriona Jamieson; Ruben Mesa; Mark Heaney; Norio Komatsu; Hironobu Minami; Yun Su; Naveed Shaik; Xiaoxi Zhang; Christine DiRienzo; Mirjana Zeremski; Geoffrey Chan; Moshe Talpaz
Journal:  Leuk Res       Date:  2019-02-28       Impact factor: 3.156

Review 5.  Novel therapies for myelofibrosis.

Authors:  Brady L Stein; Francisco Cervantes; Francis Giles; Claire N Harrison; Srdan Verstovsek
Journal:  Leuk Lymphoma       Date:  2015-05-18

6.  Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis.

Authors:  Prithviraj Bose
Journal:  Expert Opin Orphan Drugs       Date:  2019-09-24       Impact factor: 0.694

Review 7.  Definition and management of ruxolitinib treatment failure in myelofibrosis.

Authors:  A Pardanani; A Tefferi
Journal:  Blood Cancer J       Date:  2014-12-12       Impact factor: 11.037

8.  Curcumin induces apoptosis in JAK2-mutated cells by the inhibition of JAK2/STAT and mTORC1 pathways.

Authors:  Jessica Petiti; Valentina Rosso; Marco Lo Iacono; Cristina Panuzzo; Chiara Calabrese; Elisabetta Signorino; Lucrezia Pironi; Antonio Cartellà; Enrico Bracco; Barbara Pergolizzi; Tiziana Beltramo; Carmen Fava; Daniela Cilloni
Journal:  J Cell Mol Med       Date:  2019-04-29       Impact factor: 5.310

9.  Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms.

Authors:  Mengshi Hu; Tao Yang; Linyu Yang; Lu Niu; Jinbing Zhu; Ailin Zhao; Mingsong Shi; Xue Yuan; Minghai Tang; Jianhong Yang; Heying Pei; Zhuang Yang; Qiang Chen; Haoyu Ye; Ting Niu; Lijuan Chen
Journal:  Blood Cancer J       Date:  2022-03-07       Impact factor: 11.037

10.  Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study.

Authors:  Jean-Christophe Ianotto; Aurélie Chauveau; Françoise Boyer-Perrard; Emmanuel Gyan; Kamel Laribi; Pascale Cony-Makhoul; Jean-Loup Demory; Benoit de Renzis; Christine Dosquet; Jerome Rey; Lydia Roy; Brigitte Dupriez; Laurent Knoops; Laurence Legros; Mohamed Malou; Pascal Hutin; Dana Ranta; Omar Benbrahim; Valérie Ugo; Eric Lippert; Jean-Jacques Kiladjian
Journal:  Haematologica       Date:  2017-12-07       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.